(Q38317241)

2 September 2017

1 reference

title

Novel investigational drugs targeting IL-6 signaling for the treatment of depression (English)

1 reference

2 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sidney H. Kennedy

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

2

Roger S McIntyre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Trehani M Fonseka

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

14 January 2015

1 reference

Expert Opinion on Investigational Drugs

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

459-475

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25585966%20AND%20SRC:MED&resulttype=core&format=json

Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature.

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Challenging the myth of an "epidemic" of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Clinical and health services relationships between major depression, depressive symptoms, and general medical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Major depressive disorder: new clinical, neurobiological, and treatment perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Prevalence and predictors of recurrence of major depressive disorder in the adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Cytokines sing the blues: inflammation and the pathogenesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A psychoneuroimmunological review on cytokines involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Toward an anti-inflammatory strategy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A meta-analysis of cytokines in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Activation of interleukin-6 gene expression through the NF-kappa B transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 expression and regulation in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Acute-phase proteins and other systemic responses to inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6: discovery of a pleiotropic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

IL-6: regulator of Treg/Th17 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

IL-6 in autoimmune disease and chronic inflammatory proliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 and chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6, a major cytokine in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6, a mental cytokine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6: from basic science to medicine--40 years in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 trans-signalling in chronic inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Control and consequences of IL-6 receptor ectodomain shedding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The soluble Interleukin 6 receptor: generation and role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Cytokines and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

From inflammation to sickness and depression: when the immune system subjugates the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Pathways and mechanisms for cytokine signaling of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Bupropion pre-treatment of endotoxin-induced depressive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Cytokine-associated emotional and cognitive disturbances in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

T-helper-1 and T-helper-2 responses in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A review of the relationship between proinflammatory cytokines and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The relationship of depression and stressors to immunological assays: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A prospective evaluation of the directionality of the depression-inflammation relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Cerebrospinal cytokine levels in patients with acute depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Proinflammatory and "resiliency" proteins in the CSF of patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Depression, traumatic stress and interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Cytokine levels in the blood may distinguish suicide attempters from depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Melancholic and atypical major depression--connection between cytokines, psychopathology and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The HPA axis in major depression: classical theories and new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The monocyte-T-lymphocyte hypothesis of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Effects of antipsychotic drugs on cytokine networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The effect of newer serotonin-noradrenalin antidepressants on cytokine production: a review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

β-Arrestin 2 mediates the anti-inflammatory effects of fluoxetine in lipopolysaccharide-stimulated microglial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Imipramine and fluoxetine inhibit LPS-induced activation and affect morphology of microglial cells in the rat glial culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Stimulatory effect of antidepressants on the production of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Citalopram reduces endotoxin-induced fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Therapeutic targeting of the interleukin-6 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 and its receptor: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

The IL-6/sIL-6R complex as a novel target for therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Research domain criteria (RDoC): toward a new classification framework for research on mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A vision for drug discovery and development: novel targets and multilateral partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Depression, cytokines and experimental pain: evidence for sex-related association patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Cytokines and serotonin transporter in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Dysregulated relationship of inflammation and oxidative stress in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Interleukin-6 genetic polymorphism and Chinese major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Role of cytokines in atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

IL-1β, IL-6, IL-8, IL-10, IFN-γ, TNF-α and its relationship with lipid parameters in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Inflammatory changes upon a single maximal exercise test in depressed patients and healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

IL-6 levels decrease with SSRI treatment in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Trans-Signaling Is a Dominant Mechanism for the Pathogenic Actions of Interleukin-6 in the Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334

Kynurenine pathway in major depression: Evidence of impaired neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.998334